Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Cipla has informe3d that an inspection was conducted by the United States Food and Drug Administration (USFDA) at the manufacturing facility of InvaGen Pharmaceuticals Inc. (wholly owned subsidiary of the Company) located in Central Islip, Long Island, New York, USA, from 13th July, 2026 to 17th July, 2026 (EDT). The inspection was a routine current Good Manufacturing Practices (cGMP) Inspection. On conclusion of the inspection, the Company has received 1 inspectional observation in Form 483. The Company will work closely with the USFDA and is committed to address this comprehensively within stipulated time.
The above information is a part of company’s filings submitted to BSE.
